CVE:RVV

Revive Therapeutics Competitors

C$0.08

+0.01 (+14.29 %)

(As of 07/22/2019)

Add

Compare

Today's Range

C$0.08

Now: C$0.08▼

C$0.09

50-Day Range

C$0.08

MA: C$0.08▼

C$0.08

52-Week Range

C$0.07

Now: C$0.08▼

C$0.25

Volume212,852 shs

Average Volume93,085 shs

Market CapitalizationC$5.79 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Revive Therapeutics (CVE:RVV) Vs. KNE, GSD, PAS, NSP, MPH, and BTI

Should you be buying RVV stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Revive Therapeutics, including Kane Biotech (KNE), Devonian Health Group (GSD), Pascal Biosciences (PAS), Naturally Splendid Enterprises (NSP), Medicure (MPH), and Bioasis Technologies (BTI).

Revive Therapeutics vs. Kane Biotech Stock

Kane Biotech (CVE:KNE) and Revive Therapeutics (CVE:RVV) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, profitability, institutional ownership and valuation.

Profitability

This table compares Kane Biotech and Revive Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kane Biotech	N/A	N/A	N/A
Revive Therapeutics	N/A	N/A	N/A

Analyst Ratings

This is a summary of recent recommendations and price targets for Kane Biotech and Revive Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kane Biotech	0	0	0	0	N/A
Revive Therapeutics	0	0	0	0	N/A

Earnings and Valuation

This table compares Kane Biotech and Revive Therapeutics' gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kane Biotech	C$1.34 million	13.36	C$-3,801,490.00	C($0.04)	-4.71
Revive Therapeutics	N/A	N/A	N/A	C($0.02)	-3.64

Revive Therapeutics has lower revenue, but higher earnings than Kane Biotech. Kane Biotech is trading at a lower price-to-earnings ratio than Revive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Revive Therapeutics beats Kane Biotech on 2 of the 3 factors compared between the two stocks.

Revive Therapeutics vs. Devonian Health Group Stock

Devonian Health Group (CVE:GSD) and Revive Therapeutics (CVE:RVV) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, profitability, institutional ownership and valuation.

Profitability

This table compares Devonian Health Group and Revive Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Devonian Health Group	N/A	N/A	N/A
Revive Therapeutics	N/A	N/A	N/A

Analyst Ratings

This is a summary of recent recommendations and price targets for Devonian Health Group and Revive Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Devonian Health Group	0	0	0	0	N/A
Revive Therapeutics	0	0	0	0	N/A

Earnings and Valuation

This table compares Devonian Health Group and Revive Therapeutics' gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Devonian Health Group	C$1.59 million	15.20	C$-4,457,184.00	C($0.05)	-5.42
Revive Therapeutics	N/A	N/A	N/A	C($0.02)	-3.64

Revive Therapeutics has lower revenue, but higher earnings than Devonian Health Group. Devonian Health Group is trading at a lower price-to-earnings ratio than Revive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Revive Therapeutics beats Devonian Health Group on 2 of the 3 factors compared between the two stocks.

Revive Therapeutics vs. Pascal Biosciences Stock

Pascal Biosciences (CVE:PAS) and Revive Therapeutics (CVE:RVV) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, profitability, institutional ownership and valuation.

Profitability

This table compares Pascal Biosciences and Revive Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pascal Biosciences	N/A	N/A	N/A
Revive Therapeutics	N/A	N/A	N/A

Analyst Ratings

This is a summary of recent recommendations and price targets for Pascal Biosciences and Revive Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pascal Biosciences	0	0	0	0	N/A
Revive Therapeutics	0	0	0	0	N/A

Earnings and Valuation

This table compares Pascal Biosciences and Revive Therapeutics' gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pascal Biosciences	N/A	N/A	N/A	C($0.02)	-3.86
Revive Therapeutics	N/A	N/A	N/A	C($0.02)	-3.64

Pascal Biosciences is trading at a lower price-to-earnings ratio than Revive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Revive Therapeutics beats Pascal Biosciences on 1 of the 1 factors compared between the two stocks.

Revive Therapeutics vs. Naturally Splendid Enterprises Stock

Naturally Splendid Enterprises (CVE:NSP) and Revive Therapeutics (CVE:RVV) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, profitability, institutional ownership and valuation.

Profitability

This table compares Naturally Splendid Enterprises and Revive Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Naturally Splendid Enterprises	N/A	N/A	N/A
Revive Therapeutics	N/A	N/A	N/A

Earnings and Valuation

This table compares Naturally Splendid Enterprises and Revive Therapeutics' gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Naturally Splendid Enterprises	C$2.03 million	6.99	C$-9,371,678.00	C($0.04)	-1.51
Revive Therapeutics	N/A	N/A	N/A	C($0.02)	-3.64

Revive Therapeutics has lower revenue, but higher earnings than Naturally Splendid Enterprises. Revive Therapeutics is trading at a lower price-to-earnings ratio than Naturally Splendid Enterprises, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations and price targets for Naturally Splendid Enterprises and Revive Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Naturally Splendid Enterprises	0	0	0	0	N/A
Revive Therapeutics	0	0	0	0	N/A

Summary

Naturally Splendid Enterprises beats Revive Therapeutics on 2 of the 3 factors compared between the two stocks.

Revive Therapeutics vs. Medicure Stock

Revive Therapeutics (CVE:RVV) and Medicure (CVE:MPH) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation and institutional ownership.

Profitability

This table compares Revive Therapeutics and Medicure's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Revive Therapeutics	N/A	N/A	N/A
Medicure	N/A	N/A	N/A

Valuation & Earnings

This table compares Revive Therapeutics and Medicure's revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revive Therapeutics	N/A	N/A	N/A	C($0.02)	-3.64
Medicure	C$12.71 million	1.32	C$-16,189,063.70	C($1.55)	-1.04

Revive Therapeutics has higher earnings, but lower revenue than Medicure. Revive Therapeutics is trading at a lower price-to-earnings ratio than Medicure, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and price targets for Revive Therapeutics and Medicure, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revive Therapeutics	0	0	0	0	N/A
Medicure	0	0	0	0	N/A

Summary

Medicure beats Revive Therapeutics on 2 of the 3 factors compared between the two stocks.

Revive Therapeutics vs. Bioasis Technologies Stock

Revive Therapeutics (CVE:RVV) and Bioasis Technologies (CVE:BTI) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation and institutional ownership.

Profitability

This table compares Revive Therapeutics and Bioasis Technologies' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Revive Therapeutics	N/A	N/A	N/A
Bioasis Technologies	N/A	N/A	N/A

Valuation & Earnings

This table compares Revive Therapeutics and Bioasis Technologies' revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revive Therapeutics	N/A	N/A	N/A	C($0.02)	-3.64
Bioasis Technologies	C$4.12 million	5.94	C$790,284.00	C$0.01	30.91

Bioasis Technologies has higher revenue and earnings than Revive Therapeutics. Revive Therapeutics is trading at a lower price-to-earnings ratio than Bioasis Technologies, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and price targets for Revive Therapeutics and Bioasis Technologies, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revive Therapeutics	0	0	0	0	N/A
Bioasis Technologies	0	0	0	0	N/A

Summary

Bioasis Technologies beats Revive Therapeutics on 3 of the 3 factors compared between the two stocks.